Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis
|ClinicalTrials.gov Identifier: NCT00004406|
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : March 25, 2015
I. Determine the effect of human parathyroid hormone (1-34) on bone mass in middle-aged men with idiopathic osteoporosis.
|Condition or disease||Intervention/treatment|
|Osteoporosis||Drug: human parathyroid hormone|
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. All patients self-administer daily subcutaneous injections of human parathyroid hormone (1-34) or placebo for a period of 2.5 years.
Patients are followed regularly for unacceptable toxicities.
Completion date provided represents the completion date of the grant per OOPD records
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||36 participants|
|Study Start Date :||October 1999|
|Estimated Study Completion Date :||July 2004|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004406
|United States, New York|
|Columbia University College of Physicians and Surgeons|
|New York, New York, United States, 10032|
|Study Chair:||John Paul Bilezikian||Columbia University|